News

<< Back
Pulse Biosciences to Present New Data at the Society for Immunotherapy in Cancer Annual Meeting

Data to Showcase Application of Novel Nano-Pulse Stimulation Technology in Immuno-Oncology

BURLINGAME, Calif.--(BUSINESS WIRE)--Oct. 18, 2016-- Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Stimulation (NPS), today announced that it has three posters accepted for presentation at the upcoming Society for Immunotherapy in Cancer (SITC) Annual Scientific Meeting in National Harbor, Maryland, November 9 – 13, 2016.

“The presentation of this preclinical data at the prestigious SITC meeting is further evidence of the progress Pulse Biosciences is making towards validating this novel cell stimulation technology in the immuno-oncology field,” said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. “These data add to the growing body of evidence in support of NPS in immuno-oncology and further support our plans to advance into clinical studies.”

Richard Nuccitelli, Ph.D., Chief Science Officer, as well as other Pulse Biosciences scientists, will be presenting the following accepted posters:

  • “Nanosecond pulsed electric field treatment of tumor cell lines triggers Immunogenic Cell Death (ICD)”
  • "Nanosecond pulsed electric field treatment of murine melanomas initiates an immune response and inhibits metastasis”
  • "Nano-Pulse Electro Signaling treatment of murine tumors significantly reduces the percentage of regulatory T-cells in the treated tumor"

About Pulse Biosciences

Pulse Biosciences is a medical technology company developing a therapeutic tissue treatment platform based on Nano-Pulse Stimulation, a proprietary bioelectronics cell signaling technology. Published pre-clinical studies have shown that a single, brief exposure of Nano-Pulse Stimulation to target tissue stimulates a cascade of events within cells and in the surrounding microenvironment that results in apoptosis (cell death) and the priming of a durable adaptive immune response. Pulse Biosciences is pursuing a variety of applications for its technology that exploits the technology’s unique biologic effect in immuno-oncology, dermatology, aesthetics, and veterinary medicine. Clinical studies are being planned using the first commercial system designed to support a broad array of electrodes for use in superficial, minimally-invasive and open surgical procedures. More information is available at www.pulsebiosciences.com.

Source: Pulse Biosciences, Inc.

Investors:
Pulse Biosciences, Inc.
Darrin Uecker, 650-376-0042
President and Chief Executive Officer
IR@pulsebiosciences.com
or
Media:
Sam Brown, Inc.
Hannah Hurdle, 818-456-4099
hannahhurdle@sambrown.com